First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers Meeting Abstract
| Authors: | Kris, M. G.; Mok, T.; Ou, S. H. I.; Martins, R. G.; Kim, D. W.; Goldberg, Z.; Zhang, H.; Taylor, I.; Letrent, S. P.; Jänne, P. A. |
| Abstract Title: | First-line dacomitinib (PF-00299804), an irreversible pan-HER tyrosine kinase inhibitor, for patients with EGFR-mutant lung cancers |
| Meeting Title: | 10th Annual Meeting of the Japanese Society of Medical Oncology |
| Journal Title: | Annals of Oncology |
| Volume: | 23 |
| Issue: | Suppl. 11 |
| Meeting Dates: | 2012 Jul 26-28 |
| Meeting Location: | Osaka, Japan |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2012-10-01 |
| Start Page: | xi34 |
| Language: | English |
| ACCESSION: | WOS:000310634300086 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mds554 |
| Notes: | Meeting Abstract: IS7-18 -- "Source: Wos" |
